CME credits: 0.25

Valid until: 29-06-2022

Claim your CME credit at https://reachmd.com/programs/cme/applying-clinical-trial-data-on-newer-chcs-into-real-world-patient-care/12689/

The effort to reduce the estrogen concentration in combination oral contraceptives (COCs) and strike the right balance between efficacy and safety appears to be never-ending. However, a recently FDA-approved estetrol/drospirenone COC formulation offers some unique properties not seen in current COC formulations. Join us as Dr. Jeffrey Jensen and Dr. Lee Shulman discuss if this estetrol/drospirenone COC formulation will allow physicians to better address these efficacy and safety issues.